* Amylyx Pharmaceuticals Inc reported a quarterly adjusted loss of $1.07 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 30 cents. The mean expectation of five analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from $-1.26 to -42 cents per share.
* Revenue fell 99.6% to $416.00 thousand from a year ago; analysts expected zero.
* Amylyx Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.07.
* The company reported a quarterly loss of $72.7 million.
* Amylyx Pharmaceuticals Inc shares had risen by 92.0% this quarter and lost 57.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "hold"
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is 4.00 This summary was machine generated from LSEG data November 7 at 05:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.71 -1.07 Missed
Jun. 30 2024 -0.73 -0.73 Met
Mar. 31 2024 -0.01 -0.12 Missed
Dec. 31 2023 0.23 0.07 Missed
Comments